E-mail | SIS | Moodle | Helpdesk | Knihovny | cuni.cz | CIS Více

česky | english Přihlášení



Publikace členů Laboratoře od r. 1995

2021

Piataková A., Poláková I., Šmahelová J., Johari S.D., Nunvář J., Šmahel M. (2021): Distinct responsiveness of tumor-associated macrophages to immunotherapy of tumors with different mechanisms of Major Histocompatibility Complex Class I downregulation. Cancers (Basel) 13 (12): 3057 [MDPI]

Vacková J., Poláková I., Johari S.D., Šmahel M. (2021): CD80 expression on tumor cells alters tumor microenvironment and efficacy of cancer immunotherapy by CTLA-4 blockade. Cancers (Basel) 13 (8): 1935. [PubMed]

2020

Kanwal M., Šmahel M., Olsen M., Šmahelová J., Tachezy R. (2020): Aspartate β-hydroxylase as a target for cancer therapy. J. Exp. Clin. Cancer Res. 39 (1): 163. [PubMed]

Vacková J., Piataková A., Poláková I., Šmahel M. (2020): Abrogation of IFN-γ signaling may not worsen sensitivity to PD-1/PD-L1 blockade. Int. J. Mol. Sci. 21 (5): 1806. [PubMed]

2019

Lhotáková K., Grzelak A., Poláková I., Vacková J., Šmahel M. (2019): Establishment and characterization of a mouse tumor cell line with irreversible downregulation of MHC class I molecules. Oncol. Rep. 42 (6): 2826-2835. [PubMed]

Poláková I., Pelák O., Thürner D., Pokrývková B., Tachezy R., Kalina T., Šmahel M. (2019): Implementation of mass cytometry for immunoprofiling of patients with solid tumors. J. Immunol. Res. 2019: 6705949 [PubMed]

2018

Grzelak A., Poláková I., Šmahelová J., Vacková J., Pekarčíková L., Tachezy R., Šmahel M. (2018): Experimental combined immunotherapy of tumours with Major Histocompatibility Complex Class I downregulation. Int. J. Mol. Sci. 19 (11): pii: E369.3 [PubMed]

2017

Šmahel M. (2017): PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. Int. J. Mol. Sci. 18 (6): pii: E1331. [PubMed]

Šmahelová J., Kaštánková I., Poláková K.M., Klamová H., Zemanová K., Tachezy R., Hamšíková E., Šmahel M. (2017): Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia. Oncol. Rep. 37 (1): 547-554. [PubMed]

2016

Kaštánková I., Poláková I., Dušková M., Šmahel M. (2016): Combined cancer immunotherapy against Aurora kinase A. J. Immunother. 39 (4): 160-170. [PubMed]

2015

Vaculík P., Plchová H., Moravec T., Hoffmeisterová H., Čeřovská N., Šmahel M. (2015). Potato virus X displaying the E7 peptide derived from human papillomavirus type 16: a novel position for epitope presentation. Plant Cell Tiss. Org. Cult. 120 (2): 671-680. [ResearchGate]

2014

Poláková I., Dušková M., Šmahel M. (2014): Antitumor DNA vaccination against the Sox2 transcription factor. Int. J. Oncol. 45 (1): 139-146. [PubMed]

Šmahel M., Dušková M., Poláková I., Musil J. (2014): Enhancement of DNA vaccine potency against legumain. J. Immunother. 37 (5): 293-303. [PubMed]

Šmahel M., Poláková I., Dušková M., Ludvíková V., Kaštánková I. (2014): The effect of helper epitopes and cellular localization of an antigen on the outcome of gene gun DNA immunization. Gene Ther. 21 (2): 225-232. [PubMed]

2013

Čeřovská N., Moravec T., Hoffmeisterová H., Plchová H., Synková H., Poláková I., Dušková M., Šmahel M. (2013). Expression of a recombinant Human papillomavirus 16 E6GT oncoprotein fused to N-and C-termini of Potato virus X coat protein in Nicotiana benthamiana. Plant Cell Tiss. Org. Cult. 113 (1): 81-90. [ResearchGate]

** Šmahel M. (2013): Biolistic DNA vaccination against cervical cancer. In: Sudowe S., Reske-Kunt A.B. (eds): Biolostic DNA Delivery: Methods and Protocols (series Methods in Molecular Biology, vol. 940,  Springer Science + Business Media, New York, pp. 339-355. [PubMed]

2012

Čeřovská N., Hoffmeisterová H., Moravec T, Plchová H., Folwarczna J., Synková H., Ryšlavá H., Ludvíková V., Šmahel M. (2012): Transient expression of Human papillomavirus type 16 L2 epitope fused to N- and C-terminus of coat protein of Potato virus X in plants. J. Biosci. 37 (1): 125-133. [PubMed]

2011

Šmahel M. (2011): Antigens in chronic myeloid leukemia: implications for vaccine development. Cancer Immunol. Immunother. 60 (12): 1655-1668. [PubMed]

Šmahel M., Poláková I., Sobotková E., Vajdová E. (2011): Systemic administration of CpG oligodeoxynucleotide and levamisole as adjuvants for gene-gun-delivered antitumor DNA vaccines. Clin. Dev. Immunol. 2011: 176759. [PubMed]

2009

Pokorná D., Poláková I., Kindlová M., Dušková M., Ludvíková V., Gabriel P., Kutinová L., Müller M., Šmahel M. (2009): Vaccination with human papillomavirus type 16-derived peptides using a tattoo device. Vaccine 27 (27): 3519-3529 [PubMed]

2010

Poláková I., Pokorná D., Dušková M., Šmahel M. (2010): DNA vaccine against human papillomavirus type 16: modifications of the E6 oncogene. Vaccine 28 (6): 1506-1513. [PubMed]

2008

Šmahel M., Poláková I., Pokorná D., Ludvíková V., Dušková M., Vlasák J. (2008): Enhancement of T cell-mediated and humoral immunity of beta-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein. Int. J. Oncol. 33 (1): 93-101. [PubMed]

Šmahel M., Tejklová P., Šmahelová J., Poláková I., Macková J. (2008): Mutation in the immunodominant epitope of the HPV16 E7 oncoprotein as a mechanism of tumor escape. Cancer Immunol. Immunother. 57 (6): 823-831. [PubMed]

2007

Němečková Š., Šmahel M., Hainz P., Macková J., Žurková K., Gabriel P., Indrová M., Kutinová L. (2007): Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules. Neoplasma 54 (4): 326-333. [PubMed]

2005

Ludvíková V., Hamšíková E., Sobotková E., Lučanský V., Šmahel M., Vonka V. (2005): Use of polyclonal rabbit antibodies for detection of the bcr-abl fusion zone in cells transfected with experimental bcr-abl DNA vaccines. Int. J. Oncol. 27 (1): 265-274. [PubMed]

Mikysková R., Bubeník J., Vonka V., Šmahel M., Indrová M., Bieblová J., Šímová J., Jandlová T. (2005): Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy. Int. J. Oncol. 26 (2): 521-527. [PubMed]

Pokorná D., Čeřovská N., Šmahel M., Moravec T., Ludvíková V., Macková J., Synková H., Dušková M., Hozák P., Velemínský J. (2005): DNA vaccines based on chimeric potyvirus-like particles carrying HPV16 E7 peptide (aa 44-60). Oncol. Rep. 14 (4): 1045-1053. [PubMed]

Pokorná D., Macková J., Dušková M., Rittich S., Ludvíková V., Šmahel M. (2005): Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect. J. Gene Med. 7 (6): 696-707. [PubMed]

Rittich S, Dušková M., Macková J., Pokorná D., Jinoch P., Šmahel M. (2005): Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2. Oncol. Rep. 13 (2): 311-317. [PubMed]

Šmahel M., Šmahelová J., Tejklová P., Tachezy R., Jelínek F. (2005): Analysis of tumor progression by transcriptional profiling of mouse MK16 cell lines transformed with human papillomavirus type 16 E6 and E7 oncogenes and activated H-ras. Oncol. Rep. 14 (6): 1665-1674. [PubMed]

Šmahel M., Šmahelová J., Tejklová P., Tachezy R., Marinov I. (2005): Characterization of  cell lines derived from tumors induced by TC-1 cells in mice preimmunized against HPV16 E7 oncoprotein. Int. J. Oncol. 27 (3): 731-742. [PubMed]

2004

Sobotková E., Dušková M., Šmahel M., Holáň V., Janoušková O., Vonka V. (2004): Chemotherapy and immunotherapy of tumours induced by gene-modified HPV16-transformed cells. Oncol. Rep. 12 (4): 877-883. [PubMed]

Šmahel M., Pokorná D., Macková J., Vlasák J. (2004): Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase. J. Gene Med. 6 (10): 1092-1101. [PubMed]

2003

Bubeník J., Mikysková R., Vonka V., Mendoza L., Šímová J., Šmahel M., Indrová M. (2003): Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 21 (9-10): 891-896. [PubMed]

Indrová M., Bubeník J., Mikysková R., Mendoza L., Šímová J., Bieblová J., Jandlová T., Jinoch P., Šmahel M., Vonka V., Pajtasz-Piasecka E. (2003): Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int. J. Oncol. 22 (3): 691-695. [PubMed]

Janoušková O., Nellessen T., Štokrová J., Jinoch P., Šmahel M. (2003): Delivery of recombinant adeno-associated virus by jet injection. Int. J. Mol. Med. 12 (5): 687-691. [PubMed]

Jinoch P., Žák R., Janoušková O., Kunke D., Rittich S., Dušková M,, Sobotková E., Marinov I., Andělová M., Šmahel M., Vonka V. (2003): Immunization with live HPV-16-transformed mouse cells expressing the herpes simplex thymidine kinase and either GM-CSF or IL-2. Int. J. Oncol. 23 (3): 775-783. [PubMed]

Mikysková R., Bieblová J., Šímová J., Indrová M., Jandlová T., Vonka V., Šmahel M., Bubeník J., Mendoza L. (2003): Local IFN-gamma therapy of HPV16-associated tumours. Folia Biol. (Praha) 49 (1): 26-32. [PubMed]

Němečková Š.,, Šroller V., Hainz P., Kryštofová J., Šmahel M., Kutinová L. (2003): Experimental therapy of HPV16 induced tumors with IL12 expressed by recombinant vaccinia virus in mice. Int. J. Mol. Med. 12 (5): 789-796. [PubMed]

Stašíková J., Kutinová L., Šmahel M., Němečková Š. (2003): Immunization with Varicella-zoster virus glycoprotein E expressing vectors: Comparison of antibody  response to DNA vaccine and recombinant vaccinia virus. Acta Virol. 471: 1-10. [PubMed]

Šmahel M., Šíma P., Ludvíková V., Marinov I., Pokorná D., Vonka V. (2003): Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine 21 (11-12): 1125-1136. [PubMed]

Vlasák J., Šmahel M., Pavlík A., Pavingerová D., Bříza J. (2003): Comparison of hCMV immediate early and CaMV 35S promoters in both plant and human cells. J. Biotechnol. 103 (3): 197-202. [PubMed]

2002

Indrová M., Bubeník J., Mikysková R., Vonka V., Šmahel M., Žák R., Šímová J., Bieblová J., Mendoza L., Jandlová T. (2002): Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin. Int. J. Oncol. 20 (3): 643-646. [PubMed]

Šíma P., Šmahel M., Jelínek F., Vonka V. (2002): DNA vaccine against Friend erythroleukaemia virus. Folia Biol. (Praha) 48 (2): 43-50. [PubMed]

* Šmahel M. (2002): DNA vakcíny. Časopis lékařů českých 141 Suppl: 26-32. [PubMed]

2001

** Bubeník J., Šímová J., Vonka V., Šmahel M., Mikysková R., Mendoza L. (2001): Dendritic cell-based vaccines for therapy of HPV16-induced tumours. In: Mackiewicz A., Kurpisz M., Zerowski J. (eds): Progress in Basic and Clinical Immunology (series Advances in Experimental Medicine and Biology, vol. 495), Springer Science + Business Media, New York, pp. 359-363.

Indrová M., Bubeník J., Šímová J., Bieblová J., Jandlová T., Šmahel M., Vonka V, Glazman-Kusnierczyk H., Pajtasz-Piasecka E., Radzikowski C., Mikysková R. (2001): Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. Oncol. Rep. 8 (6): 1371-1374. [PubMed]

** Indrová M., Mendoza L., Reiniš M., Vonka V., Šmahel M., Němečková Š., Jandlová T., Bubeník J. (2001): Bone marrow dendritic cell-based anticancer vaccines. In: Mackiewicz A., Kurpisz M., Zerowski J. (eds): Progress in Basic and Clinical Immunology (series Advances in Experimental Medicine and Biology, vol. 495), Springer Science + Business Media, New York, pp. 355-358

Šmahel M., Sobotková E., Bubeník J., Šímová J., Žák R., Ludvíková V., Hájková R., Kovařík J., Jelínek F., Povýšil C., Marinov J., Vonka V. (2001): Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. Br. J. Cancer 84 (3): 374-380. [PubMed]

Šmahel M., Šíma P., Ludvíková V., Vonka V. (2001): Modified HPV16 E7 Genes as DNA vaccine against E7-containing oncogenic cells. Virology 281 (2): 231-238. [PubMed]

2000

Mendoza L., Indrová M., Hájková R., Reiniš M., Šmahel M., Vonka V., Bubeník J., Jandlová T. (2000): Peritumoral administration of antigen-unstimulated bone marrow-derived dendritic cells inhibits tumour growth. Folia Biol. (Praha) 46 (3): 91-97. [PubMed]

Mikysková R., Bubeník J., Mendoza L., Vonka V., Šmahel M., Šímová J., Jandlová T. (2000): Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases. Clin. Exp. Metastasis 18 (7): 581-587. [PubMed]

* Vonka V., Hamšíková E., Sobotková E., Šmahel M., Kitasato H., Sainerová H., Ludvíková V., Žák R., Kaňka J., Kolář Z., Kovařík J. (2000): Papilomaviry a lidské nádory. Časopis lékařů českých 139 Suppl 1: 27-29. [PubMed]

1999

Bubeník J., Šímová J., Hájková R., Sobota V., Jandlová T., Šmahel M., Sobotková E.,  Vonka V. (1999): Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int. J. Oncol. 14 (3): 593-597. [PubMed]

Šmahel M., Sobotková E., Vonka V., Hamšíkova E., Žák R., Kitasato H., Ludvíková V. (1999): DNA vaccine against oncogenic hamster cells transformed by HPV16 E6/E7 oncogenes  and the activated ras oncogene. Oncol. Rep. 6 (1): 211-215. [PubMed]

Tachezy R., Hamšíková E., Hájek T., Mikysková I., Šmahel M., Van Ranst M., Kaňka J., Havránková A., Rob L., Guttner V., Slavík V., Anton M., Kratochvíl B., Kotrsová L., Vonka V. (1999): Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles. J. Med. Virol. 58 (4): 378-386. [PubMed]

Vonka V., Hamšíková E., Kaňka J., Ludvíková V., Sapp M., Šmahel M. (1999): Prospective study on cervical neoplasia IV. Presence of HPV antibodies. Int. J. Cancer 80 (3): 365-368. [PubMed]

1998

Hamšíková E., Ludvíková V., Šmahel M., Sapp M., Vonka V. (1998): Prevalence of antibodies to human papillomaviruses in the general population of the Czech Republic. Int. J. Cancer 77 (5): 689-694. [PubMed]

Vonka V., Sobotková E., Hamšíková E., Šmahel M., Žák R., Kitasato H., Sainerová H. (1998): Induction of anti-tumour immunity by suicide-gene-modified HPV-16-transformed hamster cells. Int. J. Cancer 77 (3): 470-475. [PubMed]

1997

Hamšíková E., Šmahel M., Sapp M., Munoz N., Bosch F.X., Shah K.V., Vonka V. (1997): Correlation between the presence of anti HPV33 VLP antibodies and HPV DNA in cervical neoplasia patients. Arch. Virol. 142 (2): 413-416. [PubMed]

Kitasato H., Tardy-Kadlec A., Šmahel M., Tykva R., Vonka V. (1997): Putative regulatory sequence in human papillomavirus type 16 E2 open reading frame. Folia Biol. (Praha) 43 (1): 41-44. [PubMed]

1996

Kitasato H., Vonka R., Bostík P., Hamšíková E., Sobotková E., Šmahel M., Vonka V. (1996): Properties of Syrian hamster cells transformed by human papillomavirus type 16. Acta Virol. 40 (5-6): 281-288. [PubMed]

 

* Články v recenzovaných časopisech bez IF

** Kapitoly v knihách

Akce dokumentů